Eden Biologics, Inc. CEO and director Steven Lee has announced that the company has completed a deal for its contract development and manufacturing operations unit to be acquired by Bora Pharmaceuticals. The two companies entered into a definitive agreement on 10 May.
Eden’s CDMO assets are now part of Bora’s recently-established biologics CDMO platform Bora Biologics, as part of a cash transaction valued at no less than $50m and up to $65m